BridgeBio Pharma PEG Ratio

BridgeBio Pharma (BBIO) currently reports a PEG ratio of 35.75. That is above the Healthcare sector average of 12.15. Use the charts on this page to explore BridgeBio Pharma's PEG ratio history and peer comparisons.

BridgeBio Pharma's PEG ratio of 35.75 is higher than the Healthcare sector average of 12.15. That is roughly 194.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates BridgeBio Pharma's market price to a fundamental measure such as earnings, sales, or book value. At 35.75, BBIO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 35.75, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 12.15. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.

BridgeBio Pharma is classified in the Healthcare sector. On PEG ratio, it currently shows 35.75 versus a sector average near 12.15. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BBIO with unrelated industries.